Mylan’s Lower-Cost EpiPen May Not Hurt Drugmaker’s Sales Much
[...] Meanwhile, by introducing its generic, Mylan will set the market price for subsequent competitors.
“Now that there’s a product on the market for $300, any generic that enters knows that that’s the new benchmark,” said Rachel Sachs, an associate professor of law at Washington University in St. Louis. “You have to come in under $300.” [...]
Read more here!health law policy pharmaceuticals rachel sachs